Stereotaxis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on February 25, 2014, by Stereotaxis, Inc. The filing reports financial results for the fourth quarter and full year ended December 31, 2013. It also discloses a new distribution agreement in Japan and FDA clearance for the Vdrive Duo system.
Key Financial Metrics
| Metric | Q4 2013 | Q4 2012 | Full Year 2013 | Full Year 2012 |
|---|---|---|---|---|
| Total Revenue | $9.1 million | $12.2 million | $38.0 million | $46.6 million |
| System Revenue | $2.7 million | $5.6 million | $12.7 million | $19.7 million |
| Recurring Revenue | $6.3 million | $6.6 million | $25.3 million | $26.9 million |
| Operating Expenses | $8.7 million | $8.8 million | $35.9 million | $42.4 million |
| Operating Loss | Not specified | Not specified | $8.8 million | Not specified |
| Net Loss | $4.0 million ($0.23/share) | $4.3 million ($0.55/share) | $68.8 million ($5.95/share) | $9.2 million ($1.33/share) |
| Cash Burn | $1.4 million | $0.1 million | $6.3 million | $12.2 million |
| Cash and Equivalents (Year End) | $13.8 million | |||
| Total Debt (Year End) | $18.5 million | |||
| Capital Backlog (Q4 End) | $6.8 million |
Material Changes
- Revenue Decline: Q4 2013 revenue fell 25.7% year-over-year, driven by a significant drop in system sales ($2.7M vs $5.6M). Full-year revenue declined 18.5%.
- Net Loss Volatility: While Q4 net loss improved slightly on a per-share basis, the full-year 2013 net loss widened dramatically to $68.8 million. This was primarily due to a $54 million non-cash charge related to mark-to-market adjustments and amortization of convertible debt discounts.
- Expense Reduction: Full-year operating expenses decreased 15% to $35.9 million, contributing to a 16.8% improvement in operating loss compared to the prior year.
- Liquidity Improvement: Cash burn for the full year decreased 48% to $6.3 million. Cash on hand increased to $13.8 million at year-end, aided by $10.2 million in proceeds from a subscription rights offering in Q4.
Outlook, Risks, and Unusual Items
- Unusual Items: The full-year net loss includes a significant $54 million non-cash charge related to transactions with convertible note holders and equity investors.
- Strategic Developments: The Company entered into a distribution agreement with Medix Japan, Inc. and Hokushin Medical Co. Ltd. for its Niobe Magnetic Navigation System in Japan. Additionally, the FDA granted 510(k) clearance for the Vdrive Duo system with V-Sono ICE catheter manipulator on February 6, 2014.
- Operational Metrics: Companywide utilization declined 11% in 2013 compared to 2012.
- Forward-Looking Statements: The filing contains forward-looking statements regarding future performance, which are subject to risks and uncertainties. The Company does not intend to update these statements except as required by law.
Investor Verification Checklist
- Verify the impact of the $54 million non-cash charge on the reported full-year net loss and assess the sustainability of the underlying debt structure.
- Confirm the details and expected revenue contribution of the new Japan distribution agreement.
- Monitor the capital backlog of $6.8 million to gauge future system revenue visibility.
- Review the cash burn rate of $1.4 million in Q4 against the $13.8 million cash balance to estimate runway.
- Assess the 11% decline in system utilization and its potential effect on recurring revenue growth.